Skip to main content
HMGU_Icon_Environm_Health
Helmholtz Munich I Daniela Barreto

Safer Medicine: Preventing Nanoparticle-Induced Inflammation in Lung Blood Vessels

Featured Publication, Environmental Health, LHI,

Researchers around Prof. Markus Rehberg from the Institute of Lung Health and Immunity at Helmholtz Munich have discovered how engineered nanoparticles cause an undesired inflammatory response within the blood vessels in the lungs. The research team employed advanced imaging technology to study the behavior of nanoparticles and leukocytes in the alveolar region, that is essential for gas exchange. Their discovery could pave the way for safer (nano)medicines and was published in Advanced Science.

Nanoparticle-based therapeutics hold significant promise for targeted drug delivery to the lungs, thanks to the extensive pulmonary capillary network that facilitates their interaction with lung tissue. To ensure the safe application of this technology in patients, it is essential to understand the effects of engineered nanoparticles in the pulmonary microcirculation.

Cutting-Edge Imaging Sheds Light on Nanoparticle Behavior

The team of researchers employed a cutting-edge imaging technique called intravital microscopy to observe the effects of nanoparticles in the lungs of mice. This approach allowed them to see in real time how the particles interacted with the lung’s tiny blood vessels and triggered immune responses. It was the first time that such detailed insights were gained by observing the alveolar region, where gas exchange occurs in the lungs.

A Key Receptor Sparks Inflammation

Their analysis revealed that a specific receptor called P2x7 plays a key role in starting the inflammation process. When nanoparticles are present, this receptor activates the cells lining the blood vessels, which then attract immune cells, such as neutrophils, to the area. This immune reaction is part of the body’s natural response to what it perceives as a threat.

“The knowledge acquired by the research team, not only advances our understanding of pulmonary immune responses to nanoparticles but also offers a foundation for developing safer nanomedicines and addressing the side effects associated with pulmonary vascular inflammation”, so Markus Rehberg, the last author of the study.

 

Original publication

Li et al. (2024): The eATP/P2×7R Axis Drives Quantum Dot-Nanoparticle Induced Neutrophil Recruitment in the Pulmonary Microcirculation. Advanced Science. DOI: 10.1002/advs.202404661